BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice of Allowance for a patent covering methods for the use of histidyl-tRNA synthetase (HARS) Fc fusion proteins for reducing inflammation or fibrosis in the lung.

DM Clinical Research, a national network of clinical trial sites, has opened its first research location in the Boston metropolitan area and Massachusetts.

Eurofins CellTx, an industry leader in regulated testing services for living donor eligibility testing, announced the official opening of its new laboratory in Tucson, AZ.

Halia Therapeutics today announced the appointment of Dr. Margit M. Janát-Amsbury, MD, Ph.D. as the company’s Chief Medical Officer.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers.

Tallac Therapeutics, Inc. today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

SetPoint Medical today announced a senior secured term loan facility of up to $65 million from Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies.

Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.

LinKinVax and Gustave Roussy announced a collaboration to conduct a first-in-human Phase I/IIa clinical trial with CD40HVac, a new therapeutic vaccine candidate against head and neck cancer associated with human papillomavirus (HPV).

iZafe Group iZafe Group hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden.